

Βιβλιογραφικές αναφορές

1. Markou A, Tzanikou E, Lianidou E. The potential of liquid biopsy in the management of cancer patients. *Semin Cancer Biol.* 2022 Sep;84:69-79. doi:10.1016/j.semcancer.2022.03.013.
2. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic -implementation issues and future challenges. *Nat Rev Clin Oncol.* 2021 May;18(5):297-312. doi: 10.1038/s41571-020-00457-x.
3. Hanahan D. Hallmarks of Cancer: New Dimensions. *Cancer Discov.* 2022 Jan;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059.
4. Yuan D, Wei Z, Wang Y, et al. DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma. *Front Oncol.* 2021 Sep 6;11:734873. doi: 10.3389/fonc.2021.734873.
5. Goldmann T, Schmitt B, Müller J, et al. DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer. *Clin Epigenetics.* 2021;13(1):38. doi: 10.1186/s13148-021-01024-6.
6. Markou A, Londra D, Tserpeli V, et al. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection. *Clin Epigenetics.* 2022;14(1):61. doi: 10.1186/s13148-022-01283-x.
7. Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Dis- tefano N, et al. Tracking tumour evolution in glioma through liq- uid biopsies of cerebrospinal fluid. *Nature.* 2019;565(7741):654–8.
8. Muller Bark J, Kulasinghe A, Chua B, Day BW, Punyadeera C. Circulating biomarkers in patients with glioblastoma. *Br J Cancer.* 2020;122(3):295–305.
9. Jones JN, Nguyen H, Drummond K, Morokoff A. Circulating biomarkers for glioma: a review. *Neurosurgery.* 2021;88(3):E221–E230
10. Short SC, Noushmehr H. Unmet need for liquid biomarkers and the Brain-Liquid Biopsy Consortium. *Neurooncol Adv.* 2022 Nov 11;4(Suppl 2):ii1-ii3. doi: 10.1093/oaajnl/vdac020
11. Seoane J, De Mattos-Arruda L. Escaping out of the brain. *Cancer Discov.* 2014;4(11):1259–1261
12. Westphal M, Pantel K, Ricklefs FL, Maire C, Riethdorf S, Mohme M, Wikman H, Lamszus K. Circulating tumor cells and extracellular vesicles as liquid biopsy markers in neuro-oncology: prospects and limitations. *Neurooncol Adv.* 2022 Nov 11;4(Suppl 2):ii45-ii52. doi: 10.1093/oaajnl/vdac015.
13. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, et al; TCGA Research Network. The somatic genomic landscape of glioblastoma. *Cell.* 2013 Oct 10;155(2):462-77. doi: 10.1016/j.cell.2013.09.034
14. Louis, A. Perry, P. Wesseling, D.J. Brat, I.A. Cree, D. Figarella-Branger, et al., The 2021 WHO classification of tumors of the central nervous system: a summary, *Neuro Oncol.* 23 (8) (2021) 1231–125
15. Tirosh I, Suva ML. Dissecting human gliomas by single-cell RNA sequencing. *Neuro Oncol.* 2018;20(1):37–43
16. Bettgowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med.* 2014;6(224):224ra–22224
17. Friedman JS, Hertz CAJ, Karajannis MA, Miller AM. Tapping into the genome: the role of CSF ctDNA liquid biopsy in glioma. *Neurooncol Adv.* 2022 Nov 11;4(Suppl 2):ii33-ii40. doi: 10.1093/oaajnl/vdac034
18. Piccioni DE, Achrol AS, Kiedrowski LA, et al. Analysis of cell-free circu- lating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. *CNS Oncol.* 2019;8(2):CNS34.
19. Muralidharan K, Yekula A, Small JL, et al. TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomas. *Clin Cancer Res.* 2021;27(1):169–178.
20. Mouliere F, Smith CG, Heider K, et al. Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. *EMBO Mol Med.* 2021;13(8):e12881.
21. Bagley SJ, Nabavizadeh SA, Mays JJ, et al. Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma: a pilot prospective study. *Clin Cancer Res.* 2020;26(2):397–407.
22. Bagley SJ, Till J, Abdalla A, et al. Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma. *Neurooncol Adv.* 2021;3(1):vdab011.

23. Cordova C, Syeda MM, Corless B, et al. Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays. *J Clin Oncol*. 2019;37(15_suppl):2026–2026.
24. De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martinez- Ricarte F, Torrejon D, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. *Nat Commun*. 2015;6:8839.
25. Zhao Y, He JY, Zou YL, Guo XS, Cui JZ, Guo L, et al. Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis. *BMC Neurol*. 2019;19(1):331
26. Diaz M, Chudsky S, Pentsova E, Miller AM. Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors. *Transl Oncol*. 2024 Mar;41:101881. doi: 10.1016/j.tranon.2024.101881
27. Martinez-Ricarte F, Mayor R, Martinez-Saez E, Rubio-Perez C, Pineda E, Cordero E, et al. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid. *Clin Cancer Res*. 2018;24(12):2812–9
28. Bruzek A.K, K. Ravi, A. Muruganand, J. Wadden, C.M. Babila, E. Cantor, et al., Electronic DNA analysis of CSF cell-free tumor DNA to quantify multi-gene molecular response in pediatric high-grade glioma, *Clin. Cancer Res*. 26 (23) (2020) 6266–6276.
29. Izquierdo, P. Proszek, G. Pericoli, S. Temelso, M. Clarke, D.M. Carvalho, et al., Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients, *Neurooncol. Adv*. 3 (1) (2021) vdab013
30. Cantor, K. Wierzbicki, R.S. Tarapore, K. Ravi, C. Thomas, R. Cartaxo, et al., Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma, *Neuro Oncol*. 24 (8) (2022) 1366–1374
31. Juratli TA, Stasik S, Zolal A, Schuster C, Richter S, Daubner D, et al. TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas: a pilot prospective study. *Clin Cancer Res*. 2018;24(21):5282–91.
32. Pan C, Diplas BH, Chen X, Wu Y, Xiao X, Jiang L, et al. Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. *Acta Neuropathol*. 2019;137(2):297–306
33. Böhm C, Wassmann H, Paulus W. No evidence of tumour cells in blood of patients with glioma. *Mol Pathol*. 2003;56(3):187–189.
34. Sullivan J.P., Nahed B.V., Madden M.W., Oliveira S.M., Springer S., Bhere D., Chi A.S., Wakimoto H., Rothenberg S.M., Sequist L.V., et al. Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. *Cancer Discov*. 2014;4:1299–1309. doi: 10.1158/2159-8290.CD-14-0471
35. Müller C., Holtschmidt J., Auer M., Heitzer E., Lamszus K., Schulte A., Matschke J., Langer-Freitag S., Gasch C., Stoupien M., et al. Hematogenous Dissemination of Glioblastoma Multiforme. *Sci. Transl. Med*. 2014;6:247ra101. doi: 10.1126/scitranslmed.3009095
36. Perryman L., Erler J.T. Brain Cancer Spreads. *Sci. Transl. Med*. 2014;6:247fs28. doi: 10.1126/scitranslmed.3009920
37. Macarthur K.M., Kao G.D., Chandrasekaran S., Alonso-Basanta M., Chapman C., Lustig R.A., Wileyto E.P., Hahn S.M., Dorsey J.F. Detection of Brain Tumor Cells in the Peripheral Blood by a Telomerase Promoter-Based Assay. *Cancer Res*. 2014;74:2152–2159. doi: 10.1158/0008-5472.CAN-13-0813
38. Krol I., Castro-Giner F., Maurer M., Gkountela S., Szczerba B.M., Scherrer R., Coleman N., Carreira S., Bachmann F., Anderson S., et al. Detection of Circulating Tumour Cell Clusters in Human Glioblastoma. *Br. J. Cancer*. 2018;119:487–491. doi: 10.1038/s41416-018-0186-7
39. Gao F., Cui Y., Jiang H., Sui D., Wang Y., Jiang Z., Zhao J., Lin S. Circulating Tumor Cell Is a Common Property of Brain Glioma and Promotes the Monitoring System. *Oncotarget*. 2016;7:71330–71340. doi: 10.18632/oncotarget.11114
40. Eibl RH, Schneemann M. Liquid Biopsy and Primary Brain Tumors. *Cancers (Basel)*. 2021 Oct 29;13(21):5429. doi: 10.3390/cancers13215429
41. Müller Bark J, Kulasinghe A, Hartel G, et al. Isolation of circulating tumour cells in patients with glioblastoma using spiral microfluidic technology—a pilot study. *Front Oncol*. 2021;11:681130.

42. Zhang H, Yuan F, Qi Y, Liu B, Chen Q. Circulating Tumor Cells for Glioma. *Front Oncol.* 2021 Mar 10;11:607150. doi: 10.3389/fonc.2021.607150
43. Osti, D.; Del Bene, M.; Rappa, G.; Santos, M.; Matafora, V.; Richichi, C.; Faletti, S.; Beznoussenko, G.V.; Mironov, A.; Bachi, A.; et al. Clinical significance of Extracellular Vesicles in plasma from glioblastoma patients. *Clin. Cancer Res.* 2019, 25, 266–276.
44. Ricklefs FL, Wollmann K, Salviano-Silva A, Drexler R, Maire CL, Kaul MG, Reimer R, Schüller U, Heinemann S, Kolbe K, Mummert T, Glatzel M, Peine S, Gempt J, Westphal M, Dührsen L, Lamszus K. Circulating extracellular vesicles as biomarker for diagnosis, prognosis, and monitoring in glioblastoma patients. *Neuro Oncol.* 2024 Jul 5;26(7):1280-1291. doi: 10.1093/neuonc/noae068.
45. Boire, D. Brandsma, P.K. Brastianos, E. Le Rhun, M. Ahluwalia, L. Junck, et al., Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications, *Neuro Oncol.* 21 (5) (2019) 571–584.
46. Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Rudà R, Furtner J, et al; European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group (BTG) Central Nervous System (CNS) Metastases Committee and the EORTC BTG Imaging Committee. The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. *Neuro Oncol.* 2019 May 6;21(5):648-658. doi: 10.1093/neuonc/noz024.
47. Buonomo OC, Caredda E, Portarena I, Vanni G, Orlandi A, Bagni C, Petrella G, Palombi L, Orsaria P. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. *PLoS One.* 2017 Sep 18;12(9):e0184680. doi: 10.1371/journal.pone.0184680
48. Darlix A, Cayrefourcq L, Pouderoux S, Menjot de Champfleury N, Bievez A, Jacot W, Leaha C, Thezenas S, Alix-Panabières C. Detection of Circulating Tumor Cells in Cerebrospinal Fluid of Patients with Suspected Breast Cancer Leptomeningeal Metastases: A Prospective Study. *Clin Chem.* 2022 Oct 6;68(10):1311-1322
49. Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. *JAMA Oncol.* 2017 Aug 1;3(8):1069-1077. doi: 10.1001/jamaoncol.2017.0001
50. Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. *Curr Oncol.* 2013 Aug;20(4):e300-6. doi: 10.3747/co.20.1481
51. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. *Nat Rev Cancer.* 2014 Aug;14(8):535-46. doi: 10.1038/nrc3775
52. Song J, Shi J, Dong D, Fang M, Zhong W, Wang K, Wu N, Huang Y, Liu Z, Cheng Y, Gan Y, Zhou Y, Zhou P, Chen B, Liang C, Liu Z, Li W, Tian J. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy. *Clin Cancer Res.* 2018 Aug 1;24(15):3583-3592. doi: 10.1158/1078-0432.CCR-17-2507
53. Cao T, Wang G, Ren L, Li Y, Wang H. Brain tumor magnetic resonance image segmentation by a multiscale contextual attention module combined with a deep residual UNet (MCA-ResUNet). *Phys Med Biol.* 2022 Apr 19;67(9). doi: 10.1088/1361-6560/ac5e5c.
54. Klotz R, Yu M. Insights into brain metastasis: recent advances in circulating tumor cell research. *Cancer Rep (Hoboken).* 2022;5(4):e1239.
55. Zhang L, Ridgway LD, Wetzel MD, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. *Sci Transl Med.* 2013;5(180):180ra148
56. Boral D, Vishnoi M, Liu HN, et al. Molecular characterization of breast cancer CTCs associated with brain metastasis. *Nat Commun.* 2017;8(1):196.
57. Robinson SD, de Boisanger J, Pearl FMG, Critchley G, Rosenfelder N, Giamas G. A brain metastasis liquid biopsy: Where are we now? *Neurooncol Adv.* 2024 May 2;6(1):vdae066. doi: 10.1093/oaajnl/vdae066
58. Morganti S, Parsons HA, Lin NU, Grinshpun A. Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer. *NPJ Breast Cancer.* 2023 May 24;9(1):43. doi: 10.1038/s41523-023-00550-1
59. Raghavendra AS, Ibrahim NK. Breast Cancer Brain Metastasis: A Comprehensive Review. *JCO Oncol Pract.* 2024 May 15:OP2300794. doi: 10.1200/OP.23.00794

60. Hulsbergen, A. F. C. et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. *Neuro. Oncol.* 22, 1173–1181 (2020).
61. Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. *Cancer Disco.* 5, 1164–1177 (2015)
62. Li, X. et al. Clinical significance of detecting ENY-derived tumor cells in breast cancer patients with leptomeningeal metastasis. *Oncotarget* 9, 2705–2714 (2018)
63. Magbanua, M. J. M. et al. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. *Cancer Res.* 73, 7134–7143 (2013).
64. Riebensahm, C. et al. Clonality of circulating tumor cells in breast cancer brain metastasis patients. *Breast Cancer Res.* 21, 101 (2019).
65. Malani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, Seidman A, Skakodub A, Boire A, DeAngelis LM, Rosenblum M, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. *J Neurooncol.* 2020 Jul;148(3):599-606. doi: 10.1007/s11060-020-03555-z.
66. Wijetunga NA, Boire A, Young RJ, Yamada Y, Wolden S, Yu H, Kris M, Seidman A, Betof-Warner A, Diaz M, Reiner A, Malani R, Pentsova E, Yang JT. Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis. *Neurooncol Adv.* 2021 Dec 4;3(1):vdab181. doi: 10.1093/noonjnl/vdab181
67. Nevel KS, DiStefano N, Lin X, Skakodub A, Ogilvie SQ, Reiner AS, Pentsova E, Boire A. A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer. *Neuro Oncol.* 2020 May 15;22(5):675-683. doi: 10.1093/neuonc/noz208.
68. Diaz M, Singh P, Kotchetkov IS, Skakodub A, Meng A, Tamer C, Young RJ, Reiner AS, Panageas KS, Ramanathan LV, Pentsova E. Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases. *J Neurooncol.* 2022 Mar;157(1):81-90. doi: 10.1007/s11060-022-03949-1
69. Pierga, J.-Y. et al. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. *Ann. Oncol.* 24, 2999–3004 (2013).
70. Petersen, C. et al. CTCs in patients with brain metastases under radiotherapy: do they indicate treatment response? [abstract]. *Radiother. Oncol.* 133, S252–S253 (2019)
71. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. *J Clin Oncol.* 2022 Feb 10;40(5):492-516. doi: 10.1200/JCO.21.02314
72. Jacot, W. et al. Actionability of HER2-amplified circulating tumor cells in HER2- negative metastatic breast cancer: the CirCe T-DM1 trial. *Breast Cancer Res.* 21, 121 (2019).
73. Parsons, H. A. et al. Phase II single-arm study to assess trastuzumab and vinorelbine in advanced breast cancer patients with HER2-negative tumors and HER2- positive circulating tumor cells. *JCO Precis Oncol.* 5, 896–903 (2021).
74. Cortes, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. *N. Engl. J. Med.* 386, 1143–1154 (2022).
75. Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. *N. Engl. J. Med.* 387,9–20 (2022).
76. Ruan H, Zhou Y, Shen J, Zhai Y, Xu Y, Pi L, et al. Circulating tumor cell characterization of lung cancer brain metastases in the cerebrospinal fluid through single-cell transcriptome analysis. *Clin Transl Med.* 2020;10:e246.
77. White, M. D. et al. Detection of leptomeningeal disease using cell-free DNA from cerebrospinal fluid. *JAMA Netw. Open* 4, e2120040 (2021).
78. Fitzpatrick, M. Iravani, A. Mills, L. Childs, T. Alaguthurai, A. Clifford, et al., Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis, *Clin. Cancer Res.* 28 (6) (2022) 1180–1191

79. Wang Y, Luo N, Gao Y, Wu Y, Qin X, Qi Y, Sun T, Tao R, Qi C, Liu B, Yuan S. The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer. *J Cancer Res Clin Oncol.* 2023 May;149(5):1679-1690. doi: 10.1007/s00432-022-04053-7
80. Pentsova, E. I. et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. *J. Clin. Oncol.* 34, 2404–2415 (2016).
81. Angus, L. et al. Detection of aneuploidy in cerebrospinal fluid from patients with breast cancer can improve diagnosis of leptomeningeal metastases. *Clin. Cancer Res.* 27, 2798–2806 (2021)
82. Morgan AJ, Giannoudis A, Palmieri C. The genomic landscape of breast cancer brain metastases: a systematic review. *Lancet Oncol.* 2021;22(1):e7–e17
83. Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A, Weller M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. *Ann Oncol.* 2019;30(2):211–218.
84. Tivey, A., Church, M., Rothwell, D., Dive, C. & Cook, N. Circulating tumour DNA - looking beyond the blood. *Nat. Rev. Clin. Oncol.* 19, 600–612 (2022).
85. Wu J, Liu Z, Huang T, et al. Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC. *Mol Oncol.* 2023;17(5):810–824.
86. Li M, Chen J, Zhang B, et al. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028). *BMC Med.* 2022;20(1):398
87. Huang R, Xu X, Li D, Chen K, Zhan Q, Ge M, Zhou X, Liang X, Guan M. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases. *Target Oncol.* 2019 Jun;14(3):343-350. doi: 10.1007/s11523-019-00645-5.
88. Ma, J. Zhang, D. Tang, X. Ye, J. Li, N. Mu, et al., Tyrosine kinase inhibitors could be effective against non-small cell lung cancer brain metastases harboring uncommon EGFR mutations, *Front. Oncol.* 10 (2020) 224.
89. Huang WT, Lu NM, Hsu WY, Chang SE, Atkins A, Mei R, Javey M. CSF-ctDNA SMSEQ Analysis to Tailor the Treatment of a Patient with Brain Metastases: A Case Report. *Case Rep Oncol.* 2018 Feb 1;11(1):68-74. doi: 10.1159/000486568.
90. Jiang J, Gao J, Wang G, Lv J, Chen W, Ben J, Wang R. Case Report: Vemurafenib Treatment in Brain Metastases of BRAFV600E-Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection. *Front Oncol.* 2021 Jun 11;11:688200. doi: 10.3389/fonc.2021.688200.
91. Ma, X. Yang, W. Xing, H. Yu, T. Si, Z Guo, Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples, *Thorac. Cancer* 11 (3) (2020) 588–593.
92. Azad TD, Nanjo S, Jin MC, Chabon JJ, Kurtz DM, Chaudhuri AA, Connolly ID, Hui AB, Liu CL, Merriott D, Ko R, Yoo C, Carter J, Chen E, Bonilla R, Hata A, Katakami N, Irie K, Yano S, Okimoto R, Bivona TG, Newman AM, Iv M, Nagpal S, Gephart MH, Alizadeh AA, Diehn M. Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis. *NPJ Precis Oncol.* 2024 May 28;8(1):121
93. Zheng MM, Li YS, Tu HY, Jiang BY, Yang JJ, Zhou Q, Xu CR, Yang XR, Wu YL. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC. *J Thorac Oncol.* 2021 Feb;16(2):250-258. doi: 10.1016/j.jtho.2020.10.008.
94. Wu X, Xing P, Shi M, Guo W, Zhao F, Zhu H, Xiao J, Wan J, Li J. Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases. *Front Oncol.* 2022 Apr 28;12:664420. doi: 10.3389/fonc.2022.664420.
95. Siravegna G, Geuna E, Mussolin B, Crisafulli G, Bartolini A, Galizia D, Casorzo L, Sarotto I, Scaltriti M, Sapino A, Bardelli A, Montemurro F. Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. *ESMO Open.* 2017 Oct 9;2(4):e000253. doi: 10.1136/esmoopen-2017-000253.

96. Dugan, M., Fisher, D., Sweed, N., Blouw, B. & Mayer, J. Abstract PD4-03: characterization of HER2 amplification in the cerebrospinal fluid of patients with Leptomeningeal Disease in stage IV patients with breast cancer [abstract]. *Cancer Res.* 82, PD4-03 (2022).
97. Alder L, Broadwater G, Green M, Van Swearingen AED, Lipp ES, Clarke JM, Anders CK, Sammons S. Unique genomic alterations in the circulating tumor DNA of patients with solid tumors brain metastases. *Neurooncol Adv.* 2024 Apr 17;6(1):vdae052. doi: 10.1093/noajnl/vdae052.
98. Liu X, Li G, Zhang H, Chang Q, Fang M, Lu C, Tian P, Mei F. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer. *Clin Neurol Neurosurg.* 2023 Feb;225:107572. doi: 10.1016/j.clineuro.2022.107572
99. Tsakonas G, Tadigotla V, Chakraborty SK, Stragliotto G, Chan D, Lewensohn R, Yu W, Skog JK, Hydbring P, Ekman S. Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer. *Lung Cancer.* 2023 Aug;182:107292. doi: 10.1016/j.lungcan.2023.107292
100. Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, You D, Gasmi B, Viale A, Chapman PB. Quantification of tumor-derived cell free DNA (cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. *Oncotarget.* 2016 Dec 20;7(51):85430-85436. doi: 10.18632/oncotarget.13397.
101. Klein EA, Re: Sabrina HR, Grant DS. Re: Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation Set. *Eur Urol.* 2022;82:442-443. *Eur Urol.* 2022;82(5):e144
102. Nassiri F, Chakravarthy A, Feng S, et al. Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. *Nat Med.* 2020;26(7):1044-1047.
103. Barciszewska AM. Global DNA demethylation as an epigenetic marker of human brain metastases. *Biosci Rep.* 2018;38(5):BSR20180731
104. Rodrigues G, Hoshino A, Kenific CM, et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. *Nat Cell Biol.* 2019;21(11):1403-1412
105. Chen GY, Cheng JC, Chen YF, Yang JC, Hsu FM. Circulating exosomal integrin $\beta 3$ is associated with intracranial failure and survival in lung cancer patients receiving cranial irradiation for brain metastases: a prospective observational study. *Cancers (Basel).* 2021;13(3):380.
106. Li S, Qu Y, Liu L, et al. Comparative proteomic profiling of plasma exosomes in lung cancer cases of liver and brain metastasis. *Cell Biosci.* 2023;13(1):180.
107. Carretero-González A, Hergueta-Redondo M, Sánchez-Redondo S, et al. Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis. *OncoImmunology.* 2022;11(1):2067944
108. Shukuya T, Ghai V, Amann JM, et al. Circulating micrornas and extracellular vesicle-containing micrornas as response biomarkers of anti-programmed cell death protein 1 or programmed death-ligand 1 therapy in NSCLC. *J Thorac Oncol.* 2020;15(11):1773-1781.
109. Welsh JA, Goberdhan DC, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. *J Extracell Vesicles.* 2024;13(2):e12404.
110. Choi JH, Ro JY: The 2020 WHO classification of tumors of soft tissue: Selected changes and new entities. *Adv Anat Pathol* 28:44-58, 2021
111. von Mehren M, Kane JM, Agulnik M, et al: Soft tissue sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Cancer Netw JNCCN* 20:815-833, 2022
112. Frezza AM, Stacchiotti S, Gronchi A: Systemic treatment in advanced soft tissue sarcoma: What is standard, what is new. *BMC Med* 15:109, 2017
113. George S: Developments in systemic therapy for soft tissue and bone sarcomas. *J Natl Compr Cancer Netw JNCCN* 17:625-628, 2019
114. Kokkali S, Vini L, Stergioula A, Kyriazoglou A, Vassos N, Boukovinas I. Brain Metastases from Adult Sarcomas: A Retrospective Cohort Study from the Hellenic Group of Sarcomas and Rare Cancers (HGSRC). *J Clin Med.* 2021 Dec 20;10(24):5978. doi: 10.3390/jcm10245978
115. Ewongwo A, Hui C, Moding EJ. Opportunity in Complexity: Harnessing Molecular Biomarkers and Liquid Biopsies for Personalized Sarcoma Care. *Semin Radiat Oncol.* 2024 Apr;34(2):195-206. doi: 10.1016/j.semradi.2023.12.002

116. van der Laan P, van Houdt WJ, van den Broek D, Steeghs N, van der Graaf WTA. Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand? *Biomedicines*. 2021 Sep 26;9(10):1315. doi: 10.3390/biomedicines9101315
117. Satelli A, Mitra A, Cutrera JJ, et al: Universal marker and detection tool for human sarcoma circulating tumor cells. *Cancer Res* 74:1645-1650, 2014
118. Blanchi J, Laroche-Clary A, Le Loarer F, et al: Prognostic impact of circulating tumor cells in patients with soft-tissue sarcomas: A prospective study. *Cancer Commun* 43:391-394, 2023
119. Vo KT, Edwards JV, Epling CL, et al: Impact of two measures of micro- metastatic disease on clinical outcomes in patients with newly diagnosed ewing sarcoma: A report from the Children's Oncology Group. *Clin Cancer Res Off J Am Assoc Cancer Res* 22:3643-3650, 2016
120. Martín-Broto J, Pousa AL, Brohl AS, et al: Circulating tumor cells and biomarker modulation with olaratumab monotherapy followed by olaratumab plus doxorubicin: Phase Ib study in patients with soft-tissue sarcoma. *Mol Cancer Ther* 20:132-141, 2021
121. Agnoletto C, Caruso C, Garofalo C. Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice. *Cancers (Basel)*. 2021 May 2;13(9):2189. doi: 10.3390/cancers13092189
122. Samuel G, Crow J, Klein JB, et al: Ewing sarcoma family of tumors- derived small extracellular vesicle proteomics identify potential clinical biomarkers. *Oncotarget* 11:2995-3012, 2020
123. Dufresne A, Brahmi M, Karanian M, et al: Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours. *Nat Rev Clin Oncol* 15:443-458, 2018
124. Przybyl J, Chabon JJ, Spans L, et al: Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma. *Clin Cancer Res Off J Am Assoc Cancer Res* 24:2688-2699, 2018
125. Szymanski JJ, Sundby RT, Jones PA, et al: Cell-free DNA ultra-low- pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study. *PLoS Med* 18, 2021:e1003734
126. Mattox AK, Douville C, Silliman N, et al.: Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma. *Elife*. 2022 Mar 4;11:e74238. doi: 10.7554/eLife.74238.
127. Wong D, Luo P, Oldfield LE, et al: Early cancer detection in Li-Fraumeni syndrome with cell-free DNA. *Cancer Discov* 2023. <https://doi.org/10.1158/2159-8290.CD-23-0456>
128. Eastley NC, Ottolini B, Neumann R, et al: Circulating tumour-derived DNA in metastatic soft tissue sarcoma. *Oncotarget* 9:10549-10560, 2018
129. Shulman DS, Klega K, Imamovic-Tuco A, et al: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group. *Br J Cancer* 119:615-621, 2018
130. Shah AT, Azad TD, Breese MR, et al: A comprehensive circulating tumor DNA assay for detection of translocation and copy-number changes in pediatric sarcomas. *Mol Cancer Ther* 20:2016-2025, 2021
131. Serrano C, Bauer S, Gomez-Peregrina D, et al: Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. *Ann Oncol Off J Eur Soc Med Oncol* 34:615-625, 2023
132. Rolfo C, Drilon A, Hong D, et al: NTRK1 Fusions identified by non- invasive plasma next-generation sequencing (NGS) across 9 cancer types. *Br J Cancer* 126:514-520, 2022
133. Gutteridge A, Rathbone VM, Gibbons R, et al: Digital PCR analysis of circulating tumor DNA: A biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. *Cancer Med* 6:2194- 2202, 2017
134. Bui NQ, Nemat-Gorgani N, Subramanian A, et al: Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis. *Clin Cancer Res Off J Am Assoc Cancer Res* 29:2612-2620, 2023
135. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 2010;17(5):510–522.
136. Berzero G, Pieri V, Mortini P, Filippi M, Finocchiaro G. The coming of age of liquid biopsy in neuro-oncology. *Brain*. 2023 Oct 3;146(10):4015-4024. doi: 10.1093/brain/awad195

137. Sabedot TS, Malta TM, Snyder J, et al. A serum-based DNA methylation assay provides accurate detection of glioma. *Neuro Oncol.* 2021;23(9):1494–1508
138. Ferreyra Vega S, Olsson Bontell T, Corell A, et al. DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. *Clin Epigenetics.* 2021;13(1):102.
139. Malta TM, de Souza CF, Sabedot TS, et al. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. *Neuro Oncol* 2018;20(5):608–620.
140. de Souza CF, Sabedot TS, Malta TM, et al. Distinct epigenetic shift in a subset of Glioma CpG island methylator phenotype (G-CIMP) during tumor recurrence. *bioRxiv.* 2018;23(2):637–651. doi:10.1016/j.celrep.2018.03.107
- Noushmehr H, Herrgott G, Morosini NS, Castro AV. Noninvasive approaches to detect methylation-based markers to monitor gliomas. *Neurooncol Adv.* 2022 Nov 11;4(Suppl 2):ii22-ii32. doi: 10.1093/neoajnl/vdac021
141. Tesileanu CMS, van den Bent MJ, Sanson M, et al. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. *Neuro Oncol.* 2021;23(9):1547–1559.
142. Orzan F, De Bacco F, Lazzarini E, Crisafulli G, Gasparini A, Dipasquale A, Barault L, Macagno M, Persico P, et al. Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation. *Clin Cancer Res.* 2023 Apr 3;29(7):1252-1266. doi: 10.1158/1078-0432.CCR-22-2903
143. Zuccato JA, Patil V, Mansouri S, Voisin M, Chakravarthy A, Shen SY, Nassiri F, et al. Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification. *Neuro Oncol.* 2023 Aug 3;25(8):1452-1460. doi: 10.1093/neuonc/noac264
144. Cai J, Zeng C, Hua W, et al. An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas. *Neurooncol Adv.* 2021;3(1):vdab049
145. Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. *Neuro Oncol* 2010;12(2):173–180.
146. Fiano V, Trevisan M, Trevisan E, et al. MGMT promoter methylation in plasma of glioma patients receiving temozolomide. *J Neurooncol.* 2014;117(2):347–357
147. Mouliere F, Mair R, Chandrananda D, et al. Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. *EMBO Mol Med.* 2018;10(12):1–6.
148. Gattuso G, Lavoro A, Caltabiano R, Madonna G, Capone M, Ascierio PA, Falzone L, Libra M, Candido S. Methylation-sensitive restriction enzyme-droplet digital PCR assay for the one-step highly sensitive analysis of DNA methylation hotspots. *Int J Mol Med.* 2024 May;53(5):42. doi: 10.3892/ijmm.2024.5366
149. Arroyo K, Nargizyan A, Andrade FG, Myint SS, Lu S, Pandey P, Yee A, de Smith AJ, Wiemels JL. Development of a Droplet Digital™ PCR DNA methylation detection and quantification assay of prenatal tobacco exposure. *Biotechniques.* 2022 Apr;72(4):121-133. doi: 10.2144/btn-2021-0099
150. Ntzifa A, Londra D, Rampias T, Kotsakis A, Georgoulas V, Lianidou E. DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. *Cancers (Basel).* 2021 Nov 27;13(23):5974. doi: 10.3390/cancers13235974
151. Heikkinen A, Bollepalli S, Ollikainen M. The potential of DNA methylation as a biomarker for obesity and smoking. *J Intern Med.* 2022 Sep;292(3):390-408. doi: 10.1111/joim.13496. Epub 2022 Apr 19. PMID: 35404524; PMCID: PMC9543926
152. Melchers LJ, Clausen MJ, Mastik MF, Slagter-Menkema L, van der Wal JE, Wisman GB, Roodenburg JL, Schuurin E. Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma. *Epigenetics.* 2015;10(9):850-60. doi: 10.1080/15592294.2015.1075689
153. Yet I, Tsai PC, Castillo-Fernandez JE, Carnero-Montoro E, Bell JT. Genetic and environmental impacts on DNA methylation levels in twins. *Epigenomics.* 2016 Jan;8(1):105-17. doi: 10.2217/epi.15.90